Particularly the JAK1/2 inhibitor ruxolitinib was shown to decrease the JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo [75]. This evidence concerns the gene JAK1 and colorectal carcinoma.